BR112016011281B1 - Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste - Google Patents

Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste Download PDF

Info

Publication number
BR112016011281B1
BR112016011281B1 BR112016011281-4A BR112016011281A BR112016011281B1 BR 112016011281 B1 BR112016011281 B1 BR 112016011281B1 BR 112016011281 A BR112016011281 A BR 112016011281A BR 112016011281 B1 BR112016011281 B1 BR 112016011281B1
Authority
BR
Brazil
Prior art keywords
branched
linear
compound
group
benzyloxy
Prior art date
Application number
BR112016011281-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016011281A2 (US07794700-20100914-C00125.png
Inventor
Sang Ku Yoo
Jin Wook Chung
In Geun Jo
Jeong Ho Im
Ku Suk Kang
Jin Young Kim
Original Assignee
Glaceum, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaceum, Inc. filed Critical Glaceum, Inc.
Publication of BR112016011281A2 publication Critical patent/BR112016011281A2/pt
Publication of BR112016011281B1 publication Critical patent/BR112016011281B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112016011281-4A 2013-12-24 2014-12-23 Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste BR112016011281B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2013-0162909 2013-12-24
KR20130162909 2013-12-24
KR1020140181951A KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
KR10-2014-0181951 2014-12-17
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
BR112016011281A2 BR112016011281A2 (US07794700-20100914-C00125.png) 2017-08-08
BR112016011281B1 true BR112016011281B1 (pt) 2021-11-16

Family

ID=53788040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011281-4A BR112016011281B1 (pt) 2013-12-24 2014-12-23 Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste

Country Status (21)

Country Link
US (1) US9783551B2 (US07794700-20100914-C00125.png)
EP (1) EP3098224B1 (US07794700-20100914-C00125.png)
JP (2) JP6620096B2 (US07794700-20100914-C00125.png)
KR (1) KR102344479B1 (US07794700-20100914-C00125.png)
CN (1) CN105849111B (US07794700-20100914-C00125.png)
AU (1) AU2014370697B2 (US07794700-20100914-C00125.png)
BR (1) BR112016011281B1 (US07794700-20100914-C00125.png)
CA (1) CA2929001C (US07794700-20100914-C00125.png)
CY (1) CY1121554T1 (US07794700-20100914-C00125.png)
DK (1) DK3098224T3 (US07794700-20100914-C00125.png)
ES (1) ES2718878T3 (US07794700-20100914-C00125.png)
HR (1) HRP20190573T1 (US07794700-20100914-C00125.png)
HU (1) HUE043902T2 (US07794700-20100914-C00125.png)
IL (1) IL245908B (US07794700-20100914-C00125.png)
MX (1) MX2016008429A (US07794700-20100914-C00125.png)
NZ (1) NZ720328A (US07794700-20100914-C00125.png)
PL (1) PL3098224T3 (US07794700-20100914-C00125.png)
PT (1) PT3098224T (US07794700-20100914-C00125.png)
SG (1) SG11201604371PA (US07794700-20100914-C00125.png)
TW (1) TWI585093B (US07794700-20100914-C00125.png)
WO (1) WO2015099392A1 (US07794700-20100914-C00125.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
DK4023651T3 (da) * 2016-06-29 2023-11-20 Glaceum Inc Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
CA3039326C (en) 2016-10-04 2022-09-20 Glaceum Inc. Method for synthesizing 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and optical isomer of thereof
KR20190116099A (ko) 2018-04-03 2019-10-14 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
TWI804600B (zh) * 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
KR20200105198A (ko) * 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR20210014521A (ko) 2019-07-30 2021-02-09 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
WO2022260434A1 (ko) 2021-06-08 2022-12-15 주식회사 글라세움 자가면역 질환의 예방 또는 치료용 약학적 조성물
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003037316A1 (ja) 2001-10-11 2005-02-17 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤及びその製造法
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
KR20070052211A (ko) * 2005-11-16 2007-05-21 주식회사 엠디바이오알파 글라브리딘을 유효성분으로 함유하는 질환 증후군 예방 및치료용 조성물
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Also Published As

Publication number Publication date
US9783551B2 (en) 2017-10-10
CN105849111A (zh) 2016-08-10
IL245908A0 (en) 2016-08-02
TW201607949A (zh) 2016-03-01
KR102344479B1 (ko) 2021-12-29
CA2929001A1 (en) 2015-07-02
WO2015099392A1 (ko) 2015-07-02
SG11201604371PA (en) 2016-07-28
TWI585093B (zh) 2017-06-01
CA2929001C (en) 2018-02-20
AU2014370697A1 (en) 2016-06-16
EP3098224A4 (en) 2017-07-05
CN105849111B (zh) 2018-05-04
EP3098224A1 (en) 2016-11-30
IL245908B (en) 2020-08-31
PT3098224T (pt) 2019-04-26
PL3098224T3 (pl) 2019-07-31
AU2014370697B2 (en) 2017-01-19
JP6620096B2 (ja) 2019-12-11
BR112016011281A2 (US07794700-20100914-C00125.png) 2017-08-08
JP2017501163A (ja) 2017-01-12
EP3098224B1 (en) 2019-01-30
US20160272650A1 (en) 2016-09-22
HUE043902T2 (hu) 2019-10-28
JP2018135343A (ja) 2018-08-30
HRP20190573T1 (hr) 2019-05-17
CY1121554T1 (el) 2020-05-29
NZ720328A (en) 2018-02-23
KR20150075030A (ko) 2015-07-02
ES2718878T3 (es) 2019-07-05
DK3098224T3 (da) 2019-05-13
MX2016008429A (es) 2017-02-23

Similar Documents

Publication Publication Date Title
BR112016011281B1 (pt) Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste
JP7036871B2 (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
ES2802977T3 (es) Compuesto para la modulación inmunológica, uso del mismo y composición farmacéutica que lo comprende
KR20080027191A (ko) 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
US8822519B2 (en) Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof
KR102235994B1 (ko) 환상 아민 유도체의 결정 및 그 의약 용도
CN105837425B (zh) (2e, 6e)-2-(3,5-二甲氧基苯基亚甲基)-6-(4-氯苯基亚甲基)环己酮及其衍生物的新应用
US20140128418A1 (en) Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same
KR101502392B1 (ko) 이소에고마케톤을 포함하는 염증질환의 예방 또는 치료를 위한 경구투여용 약학 제형
EP4291307A1 (en) Xanthohumol derivatives and methods for making and using
NZ749461B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: GLACEUM, INC. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2014, OBSERVADAS AS CONDICOES LEGAIS.